Coleen Glessner - 09 Jun 2023 Form 4 Insider Report for Emergent BioSolutions Inc. (EBS)

Role: EVP, Quality & Ethics, and CPL
Signature: /s/ Jennifer Lynne Fox, Attorney-in-fact
Issuer symbol: EBS
Transactions as of: 09 Jun 2023
Net transactions value: $0
Form type: 4
Filing time: 13 Jun 2023, 21:22:42 UTC
Previous filing: 10 Apr 2023
Next filing: 04 Mar 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	EBS	Common Stock	Award	$0	+15,385	+13%	$0.000000	134,579	09 Jun 2023	Direct	F1, F2
transaction	EBS	Common Stock	Award	$0	+30,770	+23%	$0.000000	165,349	09 Jun 2023	Direct	F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	EBS	Employee Stock Option (Right to buy)	Award	$0	+30,770	+98%	$0.000000	62,113	09 Jun 2023	Common Stock	30,770	$8.39	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Consists of restricted stock units granted under the company's Stock Incentive Plan. These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company or the day prior to the annual shareholder meeting; whichever is earlier. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.
F2	Represents the corrected number of securities owned due to a computational error in prior Form-4s
F3	Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to both cumulative revenues and adjusted EBITDA as a percentage of total GAAP revenue calculated on a cumulative basis over the three-year period beginning January 1, 2023 and ending December 31, 2025, as certified by the Compensation Committee following the performance period. The amount reported is based on the target performance payout factor, or 100%.
F4	Vests in three equal installments beginning on the day prior to the anniversary date of the grant.